Developer docs
API playgroundTry for free, no card

Search company profiles

ALK Abelló

Full company profile

uuid000n71p

Namestring
ALK Abelló
Legal namestring
ALK-Abelló A/S
Websiteurl
alk-abello.com
Company typeenum
Public
Founded yearint
1923
Descriptiontext

ALK-Abelló A/S is a Danish specialty pharmaceutical company founded in 1923 and headquartered in Hørsholm, Denmark, publicly traded on the Copenhagen Stock Exchange under ticker ALK B. The company focuses exclusively on the prevention, diagnosis, and treatment of allergies, operating across respiratory allergy (house dust mite, pollen), food allergy (peanut), venom allergy, anaphylaxis, and related therapy areas. ALK employs 1,001–5,000 people and serves patients and healthcare professionals across Europe, North America, the Middle East, and Asia-Pacific.

The company's core technology platforms are sublingual immunotherapy (SLIT) tablets — with 20 years of clinical experience including ODACTRA for house dust mite allergy and a peanut allergy tablet in Phase 2/3 — and the EURneffy/neffy needle-free nasal adrenaline spray licensed from ARS Pharmaceuticals for anaphylaxis emergency treatment. Revenue is generated through direct commercialization in European markets (including pediatric tablet launches and EURneffy rollout in Germany and the UK), exclusive licensing arrangements in Canada (ARS Pharma), China (GenSci), and other Asia-Pacific territories, plus consumer healthcare and diagnostic product lines. Pricing is determined nationally through reimbursement systems and is not publicly disclosed.

ALK monetizes through product sales across its SLIT franchise and the EURneffy/neffy spray, supplemented by licensing upfront and milestone payments (e.g., ARS Pharma's $155M received plus up to $310M in contingent milestones, and a GenSci upfront payment contributing to 2025 free cash flow). The company resumed dividend distributions at approximately 30% of net profit in 2025 and operates with a hybrid go-to-market combining direct European field sales with channel partners across Canada, China, Japan, Australia, and the UAE. Full-year 2025 revenue was DKK 6,312 million with 15% growth and 26% EBIT margin, and Q1 2026 revenue reached DKK 1,771 million with 18% organic growth and 32% EBIT margin.

Short descriptiontext

ALK-Abelló A/S is a Denmark-based specialty pharmaceutical company founded in 1923 that develops and commercializes sublingual immunotherapy tablets and a needle-free nasal adrenaline spray for allergy prevention, diagnosis, and treatment, serving patients and clinicians across Europe, North America, the Middle East, and Asia-Pacific.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersHørsholm, Denmark
HQ citystring
Hørsholm
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
allergy immunotherapy, sublingual immunotherapy tablets, nasal adrenaline spray, allergy diagnostics, anaphylaxis treatment
Industry3 codes
PRIMARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals
SECONDARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAEAI
Allergy Immunotherapy Biologics (allergen extracts, desensitization)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Allergy Immunotherapy Pharmaceuticals
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Allergy Immunotherapy Tablets
TypeOne Time License
Description

ALK generates revenue primarily from the sale of sublingual immunotherapy (SLIT) tablets for treating respiratory allergies (house dust mite, pollen) and food allergies (peanut). In Q1 2026, total tablet sales exceeded DKK 1 billion in a single quarter for the first time. The company resumed dividend payments at DKK 355 million (approximately 30% of net profit after tax) for 2025.

globenewswire.com
2EURneffy / neffy Nasal Adrenaline Spray
TypeOne Time License
Description

Revenue from commercialization of the needle-free nasal adrenaline spray EURneffy in Europe and licensed neffy in Canada. ALK holds exclusive licensing rights to commercialize neffy in Canada, with ARS Pharma having received $155 million in upfront and milestone payments and eligible for up to $310 million in additional regulatory and sales milestones. The spray is available in 1 mg and 2 mg strengths.

in.investing.com
3Licensing and Partnership Payments
TypeLicensing Royalties
Description

ALK receives upfront payments and milestone payments from licensing partnerships, including a new Chinese partnership with GenSci that generated an upfront payment contributing to strong free cash flow of DKK 1,432 million in 2025.

globenewswire.com
4Consumer Healthcare Products
TypeHardware Sales
Description

Revenue from consumer healthcare products including diagnostics and related therapy area products, as referenced in the company's product portfolio and disease area coverage.

simplywall.st
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

ALK develops, manufactures, and commercializes allergy immunotherapy products spanning the full allergy care continuum. Its core offering is a portfolio of sublingual immunotherapy (SLIT) tablets (including ODACTRA for house dust mite allergy) for respiratory and food allergies, paired with allergy diagnostic assays and consumer healthcare products. The company has expanded into acute anaphylaxis treatment through EURneffy / neffy, the only regulatory-approved needle-free nasal adrenaline spray available in multiple strengths for adults and children.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 49% of patients tolerated 300 mg of peanut protein versus 18% on placebo (p<0.001) after 24 weeks of maintenance treatment at highest dose in Phase 2 trial
+3 more records
Product overview1 text field

ALK Abelló is a global specialty pharmaceutical company headquartered in Hørsholm, Denmark, focused on allergy diagnostics and treatments. The company offers a diversified portfolio of sublingual immunotherapy (SLIT) tablets for respiratory allergies (house dust mite, pollen) and food allergies (peanut), alongside neffy®/EURneffy, a needle-free nasal adrenaline spray for anaphylaxis emergency treatment. ALK's product portfolio spans the allergy care continuum from diagnosis through treatment, with its SLIT tablet franchise representing its core platform and neffy representing an expansion into anaphylaxis management. The company operates across all major markets through direct commercialization and licensing partnerships.

Product and service5 records
1EURneffy / neffy (Nasal Adrenaline Spray)
CategoryAnaphylaxis emergency treatment
Description

Needle-free nasal adrenaline spray for emergency treatment of anaphylaxis in adults and children. Available in 2 mg (U.S., Canada) and 1 mg (EU, UK, UAE) strengths. 88% of users prefer it over auto-injectors due to portability, ease of use, and less stigmatizing appearance.

2Sublingual Immunotherapy (SLIT) Tablets
CategoryRespiratory allergy immunotherapy
Description

ALK's flagship portfolio of sublingual immunotherapy tablets for treating respiratory allergies (house dust mite, pollen) and food allergies, built on 20 years of clinical experience and the primary platform behind total tablet sales exceeding DKK 1 billion in Q1 2026.

3ODACTRA
CategoryRespiratory allergy immunotherapy
Description

House dust mite sublingual immunotherapy tablet marketed by ALK, FDA-approved and with an expanded pediatric indication for children aged 5-11.

4Allergy Diagnostics
CategoryAllergy diagnostics
Description

Allergy diagnostic assay kits and testing products used by allergists and clinicians to identify specific allergens affecting patients, supporting targeted SLIT immunotherapy prescribing decisions.

5Consumer Healthcare Products
CategoryAllergy consumer healthcare
Description

Consumer healthcare products for allergy management and treatment, sold as part of ALK's broader allergy care continuum covering both prescription pharmaceuticals and over-the-counter allergy offerings.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

ALK entered a new Chinese partnership with GenSci for the commercialization of its allergy immunotherapy products in China. The partnership generated an upfront payment contributing to strong free cash flow of DKK 1,432 million in 2025, representing a significant strategic expansion into the Chinese market.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-11-01
Description

ALK-Abelló holds exclusive licensing rights to commercialize neffy, the epinephrine nasal spray developed by ARS Pharmaceuticals, in Canada. ARS Pharma received $155 million in upfront and milestone payments from ALK and is eligible for up to $310 million in additional regulatory and sales milestones. neffy was approved by Health Canada in April 2026 with expected launch in summer 2026.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global pharmaceutical company and maker of EpiPen, the dominant branded epinephrine auto-injector. Direct competitor to EURneffy/neffy in the emergency anaphylaxis treatment market.

TypeEmerging player
Description

Developer of Palforzia, the first FDA-approved oral immunotherapy for peanut allergy, now part of Nestlé Health Science. Competes with ALK's Phase 2 peanut SLIT tablet in the food allergy desensitization market.

TypeDirect peer
Description

UK-based specialty pharmaceutical company developing and marketing allergen-specific immunotherapy products (Pollinex Quattro, Venomil) for allergic disease treatment. Competes directly with ALK in the European allergen immunotherapy market.

TypeDirect peer
Description

Global specialty allergen immunotherapy company offering both subcutaneous (SCIT) and sublingual (SLIT) treatments for respiratory allergies. Closest direct competitor to ALK in the allergen immunotherapy tablet space and overlapping prescriber base of allergists worldwide.

TypeBroad incumbent
Description

Global pharmaceutical major with significant respiratory and allergy franchises, including dupilumab (Dupixent) for allergic conditions and historical allergen immunotherapy products. Larger competitor influencing allergy market access and reimbursement frameworks.

TypeEmerging player
Description

Clinical-stage biotech developing Viaskin epicutaneous immunotherapy (peanut, milk) for food allergies. Competes with ALK's emerging SLIT-tablet peanut franchise in the food allergy desensitization space.

7Merck KGaA (Allergopharma)
TypeBroad incumbent
Description

German life-sciences company whose Allergopharma division develops and markets allergen immunotherapy (SCIT/SLIT) products. Competes with ALK in European allergen desensitization and uses broader Merck resources to scale distribution.

TypeDirect peer
Description

European allergen immunotherapy specialist offering diagnostic and immunotherapy products (subcutaneous and sublingual) for pollen, mite, and venom allergies. Direct competitor in European markets where ALK's SLIT tablets are launched.

TypeEmerging player
Description

European specialty pharmaceutical company with growing focus on allergen immunotherapy and allergy consumer healthcare products. Competes with ALK in selected European markets in the allergy space.

TypeDirect peer
Description

Developer of neffy (epinephrine nasal spray) and ALK's licensor for European/Canadian commercialization. Highly coupled peer via the EURneffy licensing arrangement — same needle-free epinephrine product, different geographies.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment3 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ALK Abelló

Allergy Immunotherapy Pharmaceuticalsalk-abello.com

ALK-Abelló A/S is a Denmark-based specialty pharmaceutical company founded in 1923 that develops and commercializes sublingual immunotherapy tablets and a needle-free nasal adrenaline spray for allergy prevention, diagnosis, and treatment, serving patients and clinicians across Europe, North America, the Middle East, and Asia-Pacific.

What ALK Abelló does

ALK-Abelló A/S is a Danish specialty pharmaceutical company founded in 1923 and headquartered in Hørsholm, Denmark, publicly traded on the Copenhagen Stock Exchange under ticker ALK B. The company focuses exclusively on the prevention, diagnosis, and treatment of allergies, operating across respiratory allergy (house dust mite, pollen), food allergy (peanut), venom allergy, anaphylaxis, and related therapy areas. ALK employs 1,001–5,000 people and serves patients and healthcare professionals across Europe, North America, the Middle East, and Asia-Pacific.

The company's core technology platforms are sublingual immunotherapy (SLIT) tablets — with 20 years of clinical experience including ODACTRA for house dust mite allergy and a peanut allergy tablet in Phase 2/3 — and the EURneffy/neffy needle-free nasal adrenaline spray licensed from ARS Pharmaceuticals for anaphylaxis emergency treatment. Revenue is generated through direct commercialization in European markets (including pediatric tablet launches and EURneffy rollout in Germany and the UK), exclusive licensing arrangements in Canada (ARS Pharma), China (GenSci), and other Asia-Pacific territories, plus consumer healthcare and diagnostic product lines. Pricing is determined nationally through reimbursement systems and is not publicly disclosed.

ALK monetizes through product sales across its SLIT franchise and the EURneffy/neffy spray, supplemented by licensing upfront and milestone payments (e.g., ARS Pharma's $155M received plus up to $310M in contingent milestones, and a GenSci upfront payment contributing to 2025 free cash flow). The company resumed dividend distributions at approximately 30% of net profit in 2025 and operates with a hybrid go-to-market combining direct European field sales with channel partners across Canada, China, Japan, Australia, and the UAE. Full-year 2025 revenue was DKK 6,312 million with 15% growth and 26% EBIT margin, and Q1 2026 revenue reached DKK 1,771 million with 18% organic growth and 32% EBIT margin.

ALK Abelló firmographics

Firmographics
Name
ALK Abelló
Legal name
ALK-Abelló A/S
Website
https://alk-abello.com
Company type
Public
Founded year
1923
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
ALK-Abelló A/S is a Denmark-based specialty pharmaceutical company founded in 1923 that develops and commercializes sublingual immunotherapy tablets and a needle-free nasal adrenaline spray for allergy prevention, diagnosis, and treatment, serving patients and clinicians across Europe, North America, the Middle East, and Asia-Pacific.
Ownership category
akta.pro rank

ALK Abelló industry classification

Industry
Product category
Allergy Immunotherapy Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals
SECONDARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAEAI
Allergy Immunotherapy Biologics (allergen extracts, desensitization)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

  • Allergy immunotherapy
  • Sublingual immunotherapy tablets
  • Nasal adrenaline spray
  • Allergy diagnostics
  • Anaphylaxis treatment

Where ALK Abelló is headquartered

Location

Headquarters

HQ city
Hørsholm
HQ country
Denmark
HQ region
Europe

Offices1 record

Markets served

ALK Abelló business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Allergy Immunotherapy Tablets: ALK generates revenue primarily from the sale of sublingual immunotherapy (SLIT) tablets for treating respiratory allergies (house dust mite, pollen) and food allergies (peanut). In Q1 2026, total tablet sales exceeded DKK 1 billion in a single quarter for the first time. The company resumed dividend payments at DKK 355 million (approximately 30% of net profit after tax) for 2025.
  2. EURneffy / neffy Nasal Adrenaline Spray: Revenue from commercialization of the needle-free nasal adrenaline spray EURneffy in Europe and licensed neffy in Canada. ALK holds exclusive licensing rights to commercialize neffy in Canada, with ARS Pharma having received $155 million in upfront and milestone payments and eligible for up to $310 million in additional regulatory and sales milestones. The spray is available in 1 mg and 2 mg strengths.
  3. Licensing and Partnership Payments: ALK receives upfront payments and milestone payments from licensing partnerships, including a new Chinese partnership with GenSci that generated an upfront payment contributing to strong free cash flow of DKK 1,432 million in 2025.
  4. Consumer Healthcare Products: Revenue from consumer healthcare products including diagnostics and related therapy area products, as referenced in the company's product portfolio and disease area coverage.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

ALK Abelló product offering

Product offering

Core offering

ALK develops, manufactures, and commercializes allergy immunotherapy products spanning the full allergy care continuum. Its core offering is a portfolio of sublingual immunotherapy (SLIT) tablets (including ODACTRA for house dust mite allergy) for respiratory and food allergies, paired with allergy diagnostic assays and consumer healthcare products. The company has expanded into acute anaphylaxis treatment through EURneffy / neffy, the only regulatory-approved needle-free nasal adrenaline spray available in multiple strengths for adults and children.

Product overview

ALK Abelló is a global specialty pharmaceutical company headquartered in Hørsholm, Denmark, focused on allergy diagnostics and treatments. The company offers a diversified portfolio of sublingual immunotherapy (SLIT) tablets for respiratory allergies (house dust mite, pollen) and food allergies (peanut), alongside neffy®/EURneffy, a needle-free nasal adrenaline spray for anaphylaxis emergency treatment. ALK's product portfolio spans the allergy care continuum from diagnosis through treatment, with its SLIT tablet franchise representing its core platform and neffy representing an expansion into anaphylaxis management. The company operates across all major markets through direct commercialization and licensing partnerships.

Differentiator

Problem solved

Functional benefit

Products and services

  • EURneffy / neffy (Nasal Adrenaline Spray) Needle-free nasal adrenaline spray for emergency treatment of anaphylaxis in adults and children. Available in 2 mg (U.S., Canada) and 1 mg (EU, UK, UAE) strengths. 88% of users prefer it over auto-injectors due to portability, ease of use, and less stigmatizing appearance.
  • Sublingual Immunotherapy (SLIT) Tablets ALK's flagship portfolio of sublingual immunotherapy tablets for treating respiratory allergies (house dust mite, pollen) and food allergies, built on 20 years of clinical experience and the primary platform behind total tablet sales exceeding DKK 1 billion in Q1 2026.
  • ODACTRA House dust mite sublingual immunotherapy tablet marketed by ALK, FDA-approved and with an expanded pediatric indication for children aged 5-11.
  • Allergy Diagnostics Allergy diagnostic assay kits and testing products used by allergists and clinicians to identify specific allergens affecting patients, supporting targeted SLIT immunotherapy prescribing decisions.
  • Consumer Healthcare Products Consumer healthcare products for allergy management and treatment, sold as part of ALK's broader allergy care continuum covering both prescription pharmaceuticals and over-the-counter allergy offerings.

Quantifiable outcome

  • 49% of patients tolerated 300 mg of peanut protein versus 18% on placebo (p<0.001) after 24 weeks of maintenance treatment at highest dose in Phase 2 trial
  • +3 more outcomes

Companies that use ALK Abelló

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

ALK Abelló technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

ALK Abelló partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • GenSci (China)coreStrategic or Co-development Partner · 1 January 2025ALK entered a new Chinese partnership with GenSci for the commercialization of its allergy immunotherapy products in China. The partnership generated an upfront payment contributing to strong free cash flow of DKK 1,432 million in 2025, representing a significant strategic expansion into the Chinese market.
  • ARS PharmaceuticalscoreOEM/ Whitelabel/ Licensing Partner · 1 November 2024ALK-Abelló holds exclusive licensing rights to commercialize neffy, the epinephrine nasal spray developed by ARS Pharmaceuticals, in Canada. ARS Pharma received $155 million in upfront and milestone payments from ALK and is eligible for up to $310 million in additional regulatory and sales milestones. neffy was approved by Health Canada in April 2026 with expected launch in summer 2026.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

ALK Abelló competitors and assessment

Company assessment

Broad incumbents

  • Viatris (EpiPen): Global pharmaceutical company and maker of EpiPen, the dominant branded epinephrine auto-injector. Direct competitor to EURneffy/neffy in the emergency anaphylaxis treatment market.
  • Sanofi: Global pharmaceutical major with significant respiratory and allergy franchises, including dupilumab (Dupixent) for allergic conditions and historical allergen immunotherapy products. Larger competitor influencing allergy market access and reimbursement frameworks.
  • Merck KGaA (Allergopharma): German life-sciences company whose Allergopharma division develops and markets allergen immunotherapy (SCIT/SLIT) products. Competes with ALK in European allergen desensitization and uses broader Merck resources to scale distribution.

Emerging players

  • Aimmune Therapeutics (Nestlé Health Science): Developer of Palforzia, the first FDA-approved oral immunotherapy for peanut allergy, now part of Nestlé Health Science. Competes with ALK's Phase 2 peanut SLIT tablet in the food allergy desensitization market.
  • DBV Technologies: Clinical-stage biotech developing Viaskin epicutaneous immunotherapy (peanut, milk) for food allergies. Competes with ALK's emerging SLIT-tablet peanut franchise in the food allergy desensitization space.
  • Stada Arzneimittel: European specialty pharmaceutical company with growing focus on allergen immunotherapy and allergy consumer healthcare products. Competes with ALK in selected European markets in the allergy space.

Direct peers

  • Allergy Therapeutics: UK-based specialty pharmaceutical company developing and marketing allergen-specific immunotherapy products (Pollinex Quattro, Venomil) for allergic disease treatment. Competes directly with ALK in the European allergen immunotherapy market.
  • Stallergenes Greer: Global specialty allergen immunotherapy company offering both subcutaneous (SCIT) and sublingual (SLIT) treatments for respiratory allergies. Closest direct competitor to ALK in the allergen immunotherapy tablet space and overlapping prescriber base of allergists worldwide.
  • HAL Allergy: European allergen immunotherapy specialist offering diagnostic and immunotherapy products (subcutaneous and sublingual) for pollen, mite, and venom allergies. Direct competitor in European markets where ALK's SLIT tablets are launched.
  • ARS Pharmaceuticals: Developer of neffy (epinephrine nasal spray) and ALK's licensor for European/Canadian commercialization. Highly coupled peer via the EURneffy licensing arrangement — same needle-free epinephrine product, different geographies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

ALK Abelló social profiles

Digital presence

ALK Abelló financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ALK Abelló leadership team

Management profile

Number of profiles

Profiles5 records

ALK Abelló subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

ALK Abelló funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ALK Abelló M&A and investment

M&A and investment

M&A2 records

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ALK Abelló

What does ALK Abelló do?

ALK develops, manufactures, and commercializes allergy immunotherapy products spanning the full allergy care continuum. Its core offering is a portfolio of sublingual immunotherapy (SLIT) tablets (including ODACTRA for house dust mite allergy) for respiratory and food allergies, paired with allergy diagnostic assays and consumer healthcare products. The company has expanded into acute anaphylaxis treatment through EURneffy / neffy, the only regulatory-approved needle-free nasal adrenaline spray available in multiple strengths for adults and children.

Is ALK Abelló a public or private company?

ALK Abelló is a public company. It is classified as public and is currently operating.

When was ALK Abelló founded?

ALK Abelló was founded in 1923. It employs 1,001 to 5,000 people.

Where is ALK Abelló based?

ALK Abelló is headquartered in Hørsholm, Denmark, in the Europe region.

How does ALK Abelló make money?

Four revenue lines are on record. Allergy Immunotherapy Tablets are the primary driver. The others are EURneffy / neffy Nasal Adrenaline Spray, licensing and Partnership Payments and consumer Healthcare Products.

Who are ALK Abelló's main competitors?

Broad incumbents on record are Viatris (EpiPen), Sanofi and Merck KGaA (Allergopharma). Emerging players are Aimmune Therapeutics (Nestlé Health Science), DBV Technologies and Stada Arzneimittel. Direct peers are Allergy Therapeutics, Stallergenes Greer, HAL Allergy and ARS Pharmaceuticals.

Does ALK Abelló have an API?

No public API is recorded for ALK Abelló.

What industry is ALK Abelló in?

ALK Abelló's product category is Allergy Immunotherapy Pharmaceuticals. Its primary akta.pro industry code is HLAIACAF, Pulmonology & Allergy Specialty Pharmaceuticals, with a secondary code of HLAIAAAH, Respiratory & Allergy Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comALK at Jefferies Global Healthcare Conference: growth broadensALK Therapeutics reported 15% overall growth in the latest quarter, driven by 35% growth in its tablets business. Management said it exceeded its 10% top-line growth target and reiterated a 25% operating margin target. Germany's rebate rose to 15.5%, a headwind management is mitigating.Seeking AlphaALK-Abelló A/S GAAP EPS of DKK1.60, revenue of DKK1.76BALK-Abelló A/S reported Q3 GAAP EPS of DKK1.60 and revenue of DKK1.76B, up 15% year-over-year. The company's stock closed at DKK36.50, up 8.31%.Seeking AlphaALK-Abelló A/S (AKBLF) Q3 2026 Earnings Call TranscriptALK-Abelló reported Q3 revenue of DKK 1.76 billion, up 15% in local currency, with tablets growing 35% to DKK 999 million. Operating profit EBIT rose 9% to DKK 469 million, and the EBIT margin was 27% versus 28% a year earlier.TradingViewALK_B: Tablet-led growth drove Q3; reaffirmed guidance and capacity expansion underpin the outlookALK-abello A/S reported Q3 2026 revenue growth of 15% in local currencies, led by tablets, with a 9M EBIT margin of 28%. The company reaffirmed its full-year guidance, citing growth investment, China trial progress, and expanded tablet capacity as supporting factors.TradingViewALK-Abelló Q3 2026 Earnings Call Is LiveALK-Abelló's Q3 2026 earnings call is live, with executives set to discuss financial results and answer analyst questions. Management commentary on demand, margins, or capital spending may move markets.TradingViewALK_B: Tablet-led growth lifted Q3 revenue 15%; FY2026 growth guidance rose to 16–17%ALK-abello A/S reported Q3 revenue growth of 15% year-over-year in local currencies, driven by tablet sales. Operating profit rose 16% to 9M, and free cash flow reached DKK 1,192m. The company raised its FY2026 revenue growth guidance to 16-17%.GlobeNewswireNine-month interim report (Q3) 2026 (unaudited)ALK reported Q3 2026 revenue of DKK 1,764 million, up 15% year-over-year, with tablet sales growing 35% to DKK 999 million. Operating profit rose 9% to DKK 469 million, and the company confirmed its upgraded full-year outlook. The company expects revenue growth of 16-17% in local currencies for 2026.TradingViewALK-Abelló A/S Reports Managerial Staff TransactionsALK-Abelló A/S reported managerial staff transactions in its B shares and associated securities under Article 19 of the Market Abuse Regulation. The release provides no transaction details, and the attached announcement would be needed to identify the securities, transaction type, size, and dates.InvestegateReport on transactions with ALK-Abelló A/S B shares and associated securities by managerial staffALK-Abelló reported that managerial staff transactions in B shares and associated securities were filed under Article 19 of the EU Market Abuse Regulation. The release does not disclose quantities, values, percentages, or trade dates, so the impact on the share price cannot be assessed from this announcement alone.Ticker ReportALK-Abelló A/S (OTCMKTS:AKBLF) Shares Climb 8.3% – Here’s What HappenedALK-Abelló shares rose 8.3% to $36.50 during mid-day trading on Wednesday, with volume up 127% to 1,197 shares. The stock closed at $33.70 and trades above its 50-day moving average of $34.46.